Oncolytic adenoviruses (Ad) have been developed for the eradication of tumors. Although they hold much promise as a cancer therapy, they have a short blood circulation time and high liver toxicity. An effective strategy to overcome these problems has been complexing Ad with shielding materials. However, the therapeutic efficacy of the Ad complexes has also been an issue because passive accumulation does not allow for sufficient delivery of Ad to the cancer cells. To enhance the therapeutic efficacy of the polymer-coated Ads, the attachment of a targeting moiety to polymer-coated Ad vectors is inescapable. Our lab has previously reported the potential use of Arg-Gly-Asp (RGD)-targeted bioreducible polymers with a polyethylene glycol (PEG) linker for delivering oncolytic Ads. We have shown the enhanced in vitro transduction efficiency and increased cancer-killing effect with producing progeny oncolytic Ad particles. In addition, we have shown significant tumor-growth inhibition of the polymer-shielded Ad in an in vivo lung orthotopic tumor model. The shielding effect of the Ad surface with the polymers allowed evasion of host immune responses and reduction of liver toxicity. This data demonstrates that the RGD-conjugated bioreducible polymer for delivering the oncolytic Ad vectors could be utilized for cancer therapy via systemic administration.
INTRODUCTION
With dl/1520, also known as ONYX-015 first in order, 1, 2 development of oncolytic adenovirus (Ad) vectors has been intensively highlighted in the field of cancer gene therapy because of their cancer-selective replication and anti-tumor effects. These properties come from the modification of Ad genomic portions such as E1A and/or E1B regions. [3] [4] [5] By using the dysfunctional cellular defense mechanism in cancer cells, these oncolytic Ads with deletion or substitution of E1A gene and/or deletion of E1B genes have shown promising outcomes. 4, 5 For more selectivity in specific types of cancers, introduction of tumor-specific promoters and enhancers derived from many kinds of cancer-specific elements such as prostate-specific antigen, 6 α-fetoprotein, 7 carcinoembryonic antigen, 8 human telomerase reverse transcriptase 9 or hypoxia responsive element, 10 have been successful. On the other hand, a variety of therapeutic genes such as tumor-suppressor genes, 11 suicide genes, 12, 13 immune-stimulatory cytokine gene, 14, 15 small interfering RNA (siRNA) 16, 17 or genes for efficient viral spread [18] [19] [20] have been introduced into the Ad genome to enhance cancerkilling potency of the oncolytic Ad vectors. Despite many advantages of the oncolytic Ad vectors, in vivo application of the vehicles is limited to local injections because the systemically administered Ad particles are immediately eliminated because of innate/adaptive host immune responses, liver-tropism of Ad and absence of tumor-targeting moiety. 21, 22 Thus, intravenously injected Ad vectors can be quickly cleared biologically before the particles localize into the tumor area and infect the cancer cells. [23] [24] [25] To prolong blood circulation time and reduce liver toxicity of the intravenously injected Ad vectors, the very simple but brilliant concept to shield the surface of the therapeutic Ad particles with nonimmunogenic polyethylene glycol (PEG) was introduced. 26 The techniques to coat therapeutic Ad vectors with synthetic polymers shielding immunogenic Ad surface and attenuating the nature of liver-tropism of Ad, have been successfully adopted. [27] [28] [29] [30] The extended blood circulation time and loss of liver-tropism of Ad particles caused by the polymers increased the chance of Ad accumulation within the solid tumor area because of the well-known enhanced permeability and retention effect and the ability of the coated Ad to infect the cancer cells by charge-interaction between the positively charged polymers and negatively charged cellular membranes. 31, 32 However, although the passively accumulated Ad particles delivered by the polymers could reach the tumor area through the leaky vasculature of solid tumors, sufficient therapeutic efficacy by passive accumulation would not be expected because the natural stealth effects of the polymer reduces the transduction efficiency. 28, 33, 34 To enhance the therapeutic efficacy of oncolytic Ad vectors, attaching targeting moieties to the polymer carrier delivering the Ad particles is a convenient and effective strategy. 33, 34 Arg-GlyAsp (RGD), a cancer cell-binding/penetrating peptide, is one of the most popular and effective candidates for biological delivery of cancer drugs and nanoparticles to tumor-specific vessels. It is well known that RGD triad peptides can easily bind with high affinity and endocytotic ability to αv-integrins which are important biomarkers overexpressed in sprouting tumor vessels and most tumor cells. [35] [36] [37] In addition to shielding immunogenic Ad surfaces with nonimmunogenic polymers, we have previously introduced the cyclic RGD (cRGD)-conjugated bioreducible polymers for delivering oncolytic Ad. These polymers showed low cytotoxicity, high oncolytic effects, and characteristics of exclusive-and activetargeting to cancer cells expressing αv-integrins when compared with that of naked Ad or untargeted polymer-shielded Ad. 38 The biodegradable poly(cystaminebisacrylamide-diaminohexane) [poly(CBA-DAH)] (CD) conjugated with cRGD peptide using the hetero-bifunctional cross linker PEG 500 (PEG 0.5 k) or PEG 2000 (PEG 2.0 k) was utilized 38, 39 because the CD polymer shows low cytotoxicity and high efficiency of gene transfection and can be biodegraded to non-toxic small molecules upon exposure to the reductive environment of the cytoplasm via the cleavage of disulfide bonds by glutathione. 39, 40 In this study, we compared the cancer-killing effects and the viral production of the oncolytic Ad delivered by the RGDconjugated polymers to nontargeted branched polyethyleneimine (bPEI, MW 25 000). For in vivo therapeutic profile, we determined the tumor growth suppression and the ability to evade host immune responses of the polymer-shielded Ads in orthotopic tumor models via systemic administration.
RESULTS

Enhanced transduction efficiency
It is well-known that Ad infectivity into tumor cells is poor because CAR expression on malignant cancer cells is downregulated frequently. 41 Therefore, the techniques for coating of Ad surfaces with cationic polymers are widely utilized to increase the transduction efficacy and enhance the cancer-killing effect of the Ad vectors. [28] [29] 33 As we previously reported, 38 different expression patterns of CAR proteins and integrins on the surface of human cancer cells (A549, HT1080 and MCF7) were observed. 38 In the case of HT1080 human fibrosarcoma cell line, low CAR expression and high integrin expression were detected on their surfaces. Using this cell line (HT1080), we evaluated the transduction efficiency of the naked Ad, the Ad coated with the bioreducible polymers and commercial bPEI polymers as an experimental control group. The replication-incompetent naked Ad (GAd) encoding GFP gene or the Ad physically complexed with the polymers (GAd/bPEI, GAd/CD, GAd/CD-PEG 500 -RGD or GAd/ CD-PEG 2000 -RGD) was treated to HT1080 cancer cells for 4 h and allowed to express the transgene for 48 h. Figure 1a shows that the dramatically enhanced transgene expression of the Ad in the cancer cells was observed under fluorescent microscopy when the Ad surfaces were physically coated with the bioreducible cationic polymers (CD, CD-PEG 500 -RGD or CD-PEG 2000 -RGD), in marked Enhanced cancer-killing effect and increased viral production To assess the cancer cell-killing effect and viral production of naked Ad (oAd) or the polymer-shielded Ad (oAd/CD, oAd/CD-PEG 500 -RGD or oAd/CD-PEG 2000 -RGD) in the cancer cells, oAd or the polymer-shielded Ad was administered to the cancer cells to evaluate their killing effects by MTT assay (Figure 2a ) and progeny viral production by end-point analysis (Figure 2b ). The cancer-killing effect of the polymer-shielded Ad (oAd/CD, oAd/CD-PEG 500 -RGD or oAd/CD-PEG 2000 -RGD) in HT1080 cancer cells was shown to be 67.5, 83.5 or 60.0%, respectively, whereas naked oAd showed only 12% of the killing effect. In the viral production assay (Figure 2b ), the cancer cells treated with the polymer-shielded Ad (oAd/CD, oAd/CD-PEG 500 -RGD or oAd/CD-PEG 2000 -RGD) produced 343-, 1643-or 257-times higher progeny viruses than those with the naked Ad. These results indicate that the enhanced transduction efficiency ( Figure 1 ) and the killing effect of the Ad coated with the bioreducible polymers are correlated with the increased progeny viral production. Especially, the Ad coated with CD-PEG 500 -RGD polymer showed the strongest transduction efficiency (Figure 1 ), oncolytic effect and the highest viral production efficacy in the cancer cells ( Figure 2 ). Although the degree of PEGylation of the Ad surfaces could increase the blood circulation time and decrease the accumulation in liver, larger-sized PEG can reduce the transduction efficiency of the Ad vectors. 42 Thus, we assume that the enhanced killing efficiency and viral production of the oAd/CD-PEG 500 -RGD when compared with the oAd/CD-PEG 2000 -RGD is attributable to the shorter-sized PEG molecules of the polymer (CD-PEG 500 -RGD) being more effective at delivering the Ad vectors.
Evading innate and adaptive immune response Systemically administered naked Ad particles are rapidly extinguished because of host biological defense mechanisms such as innate and adaptive immune response. 21, [23] [24] [25] Macrophages and dendritic cells secreting proinflammatory cytokines such as interleukin-6 (IL-6) and the existence of widespread anti-Ad neutralizing antibodies (Ab) in individuals exposed to Ad before are the major barriers that need to be overcome to achieve the efficient systemic delivery of Ad. RAW264.7, a murine macrophage cell line, is known to induce innate immune response against Ad particles. These cells were treated Ad vector coated with CD, CD-PEG500-RGD or CD-PEG2000-RGD polymers, and the secretion levels of IL-6 was evaluated. As shown in figure 3a , the amount of the secreted IL-6 from the cells treated with the naked Ad was 5.0-fold higher than that of PBS. However, IL-6 secretion was not significantly different from the control in cells treated with the polymer-shielded Ad (Ad/CD, Ad/CD-PEG500-RGD or Ad/CD-PEG2000-RGD), demonstrating that the shielding of Ad surface with CD polymer may reduce the innate immune response against Ad.
To evaluate the ability of the polymer-shielded Ad to prevent the induction of neutralizing Ab against Ad, naked Ad or each polymer-shielded Ad (Ad/CD, Ad/CD-PEG 500 -RGD or Ad/CD-PEG 2000 -RGD) was incubated with naïve serum or the serum containing anti-Ad Ab for 30 min at 37°C. As shown in Figure 3b , there was no significant difference of the transduction efficiency by each polymer-shielded Ad group in the cells, whereas the transduction efficiency of the cells treated with naked Ad incubated with the serum including anti-Ad neutralizing Ab was dramatically reduced by 95.3% compared with that by the heat-inactivated serum without the neutralizing Ab. Taken together, these results demonstrated that the shielding of Ad with the polymer may reduce macrophage and antibodymediated immunity. Liver toxicity When naked Ad is systemically injected, the highest responsive human organ is the liver. The naked Ad causes acute accumulation in liver followed by hepatotoxicity. 43 Therefore, we determined the liver serum ALT and AST levels after intravenous injection of naked Ad or the polymer-shielded Ad (oAd/CD, oAd/CD-PEG 500 -RGD or oAd/CD-PEG 2000 -RGD). As shown in Figure 5a , the mice received with naked Ad had significantly higher serum levels at 2 days after injection than PBS controls (P o0.05). In contrast, there was no significant increase in ALT and AST levels from the serum of the mice injected with the polymer-shielded Ad. Furthermore, the histopathological analysis by hematoxylin and eosin staining demonstrated that the liver section of the mouse intravenously injected with the naked Ad showed typical hepatotoxicity such as hepatocellular swelling, nuclei degeneration and absence of chromatin margins (yellow arrows), whereas the liver sections of the mice systemically received with PBS or the polymer-shielded Ad (oAd/CD-PEG 500 -RGD or oAd/CD-PEG 2000 -RGD) did not show any Ad-induced hepatic injury (Figure 5b ). This data indicates that the RGD-targeted nonimmunogenic polymers shielding the oncolytic Ad particles via systemic administration reduce the liver 
DISCUSSION
We previously reported that the bioreducible CD polymer, as a potential carrier for gene delivery, showed high transfection efficiency for delivering plasmid DNA and had significantly less cytotoxicity than the bPEI due to its biodegradability and was effectively localized to the cytoplasm. 39 To further develop a more intelligent and effective version of the polymer for in vivo application to deliver therapeutic Ad vectors, cRGD peptide ligand, which selectively recognizes both αvβ3 and αvβ5 integrin receptors that are known to be overexpressed in endothelial cells of tumor capillaries, was conjugated onto the CD polymer. This was done using PEG cross linkers of different sizes (PEG 500 or PEG 2000 ), which can enhance stability in blood after systemic administration. 38 The RGD-conjugated bioreducible polymers (CD-PEG 500 -RGD or CD-PEG 2000 -RGD) blocked the typical infection pathway of naked Ad and created an alternative infection pathway via binding of the RGD-targeting peptide with integrins on target cells. 38 Using a competitive assay by blocking receptor on the target cell with CAR Ab or integrin (αvβ3 and αvβ5) Abs, the entry of the Ad coated with CD-PEG 500 -RGD or CD-PEG 2000 -RGD was shown to be mediated by an integrin-dependent pathway and to be independent of the normal CAR-mediated pathway. 38 On the basis of the data, we concluded that the RGD-conjugated bioreducible polymers (CD-PEG 500 -RGD or CD-PEG 2000 -RGD) 10 VP of Ad with the polymers (3 × 10 5 molecules per Ad particle). ANOVA followed by Tukey multiple comparison test; *P o0.01 versus PBS; enhanced the transduction efficacy of the oncolytic Ads to cancer cells selectively expressing integrins. 38 As we showed in our previous result, the oncolytic Ad (Ad-ΔB7-U6shIL8: oAd) complexed with the bioreducible polymers showed significantly increased oncolytic effects in human cancer cells expressing high levels of αv-integrins, while sparing human normal cells. 38 This enhanced cancer-killing effect of the oncolytic Ad delivered by the polymers (CD, CD-PEG 500 -RGD or CD-PEG 2000 -RGD) was directly correlated not only with the suppression of IL-8 and VEGF expression levels and induction of intense apoptosis, but also with the increased viral production in human cancer cells (Figure 2b ).
In the in vivo study, we demonstrated the significant suppression of the tumor growth by the oAd delivered by RGD-targeted polymers when compared with that by nontargeted polymers in orthotopic and subcutaneous models (Figure 4) . In general, the degree of PEGylation for Ad coating can increase the blood circulation time and the tumor accumulation ratio. 44, 45 The largersized PEG especially reduces liver transduction, resulting in the prolonged circulation time of the Ad. 42 We believe that the longer PEG chain (PEG 2000 ) of the CD-PEG 2000 -RGD polymer could prolong the blood circulation time after systemic injection and increase the stability of the polymer. [42] [43] [44] [45] Although systemic delivery of the naked Ad induced the strong innate and adaptive immune responses, the polymer-shielded Ads successfully escaped from the host immune reactions (Figure 3) . Not only that, liver toxicity induced by the capsid proteins of the Ad vectors via systemic injection was significantly decreased by coating with the nonimmunogenic polymers.
In addition to treating primary tumors, a successful oncolytic Ad vector for cancer gene therapy could also be used to treat metastatic tumors. We here suggest the use of RGD-conjugated bioreducible polymers for systemic delivery of the oncolytic Ad vectors. We have demonstrated that the polymer-shielded Ad can enhance the transduction efficiency and the cancer-killing effect by producing the progeny infectious oncolytic Ad particles, and also successfully evade host innate and adaptive immune responses. Moreover, the targeted polymer-shielded Ad was more effective at inhibiting tumor growth than the nontargeted polymer-shielded Ad in a lung orthotopic tumor model, indicating better therapeutic efficacy. In conclusion, this study through in vitro assays and in vivo experiments as well, demonstrate that the RGD-conjugated bioreducible polymer could be utilized for delivering the oncolytic Ad vectors via systemic administration.
MATERIALS AND METHODS
Cell lines and Ad vectors
Human fibrosarcoma (HT1080), lung adenocarcinoma (A549) and embryonic kidney 293 cells were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA). All cell lines were maintained and cultured in high glucose Dulbecco's modified Eagle's Media (DMEM) containing 10% fetal bovine serum (FBS) in 37°C incubator with 5% CO 2 . The construction of replication-incompetent Ad encoding GFP gene (Ad-ΔE1/GFP) was characterized in our previous report. 4 Cancer-selective replicating oncolytic Ad (Ad-ΔB7-U6shIL8: oAd) expressing shRNA against IL-8 RNA were described previously. 17 In brief, this oncolytic Ad (oAd) has two mutations at E1A gene for binding with retinoblastoma proteins (pRb) and deletions of E1B genes for binding with p53 proteins. 5 Thus, this virus can conditionally replicate in and eventually kill cancer cells harboring tumor suppressor-dysfunctional pathways, as the defective pathway of tumor suppressor genes such as pRb, p53 and/or p14ARF is frequently reported in human cancer cells. [1] [2] [3] [4] [5] The polymers and Ad/polymer complex The process for synthesizing CD polymer or RGD-conjugated bioreducible polymers (CD-PEG 500 -RGD or CD-PEG 2000 -RGD) was introduced in our previous work. 38, 39 In brief, the conjugation of cRGD peptides to CD was performed using hetero-bifunctional cross linker SM(PEG 500 ) or SM (PEG 2000 ) (Pierce, Rockford, IL, USA). The CD was activated with 5 molar equivalents of SM(PEG 500 ) or SM(PEG 2000 ) per 10 DAH groups in anhydrous dimethyl formamide for 4 h at room temperature and purified with a desalting column. Cysteine-terminated cRGDfC (2 eq) was added to the activated polymer and the reaction mixture was stirred for 24 h under the dark condition at room temperature. The crude mixture was precipitated with cold ether and purified by extensive dialysis against ultra pure water. The conjugation of cRGDfC linked with PEG 500 or PEG 2000 was confirmed 
Oncolytic effect assay
After seeding human fibrosarcoma cells (HT1080) on a 24-well plate at 70% of confluence 1 day before treatment, the cells were treated with naked oncolytic Ad (oAd) or the polymer-shielded Ad at an MOI of 50 with the corresponding polymers (bPEI: 1 × 10 5 molecules per VP; CD, CD-PEG 500 -RGD or CD-PEG 2000 -RGD: 3 × 10 5 molecules per VP) for 4 h, then each medium was replaced with DMEM containing 5% FBS. After incubation for 2 days allowing viral replication and cell-lysis, the medium was replaced with fresh medium containing 400 μg ml − 1 of MTT, (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide). Subsequently, the cells were incubated at 37°C for 4 h under dark condition. The MTT solution was removed and replaced with 500 μl of dimethyl sulfoxide (DMSO) to solubilize the produced formazan crystals. The absorbency was determined using a microplate reader (Bio-Rad 680, Hercules, CA, USA) at 540 nm. The cell viability was expressed as the percentage of untreated cells as a negative control. Each experiment was repeated three times.
Viral production assay
The progeny viral productions of naked oncolytic Ad (oAd) or each polymer-shielded Ad in human fibrosarcoma cells (HT1080) were quantified by end-point dilution assay. 4 The HT1080 cells treated with each experimental group (mentioned at the above paragraph, 2.4. oncolytic effect assay) for 4 h incubation were harvested after incubation for 2 days allowing viral replication and cell-lysis. The generated infectious Ad particles (plaque forming unit) from cellular supernatants and lyzates were determined using 293 cells. 
Adaptive immune response
To evaluate adaptive immune response, Balb/c mouse was received with naked Ad at a single dose of 1 × 10 10 VP intravenously. Mouse serum immunized with or without naked Ad was harvested at 14 days after second injection with the same dose of Ad and inactivated at 56°C for 45 min to inactivate blood complement and stored at − 20°C for neutralization protection assay. Naked Ad (50 MOI) or Ad coated with the polymers (CD, CD-PEG 500 -RGD or CD-PEG 2000 -RGD: 3 × 10 5 molecules per VP) was exposed to naïve serum or the serum with Ad-specific neutralizing antibody (Ab), for 30 min at 37°C and then treated to human cancer cells (A549). After 2 days of incubation, each GFP expression was quantified by the fluorescent analyzer.
Liver toxicity test
To measure liver toxicity of the naked Ad or the polymer-shielded Ad (Ad/CD, Ad/CD-PEG 500 -RGD or Ad/CD-PEG 2000 -RGD), a single dose of 1 × 10 10 VP of naked Ad or the polymer-shielded Ad (polymers: CD, CD-PEG 500 -RGD or CD-PEG 2000 -RGD, 3 × 10 5 molecules per VP) was injected intravenously into each Balb/c mouse. After 2 days post injection, the serum levels of ALT and AST were measured. Subsequently, each mouse was sacrificed and liver tissues were harvested and embedded in paraffin for hematoxylin and eosin staining.
Statistical analysis
The data were expressed as the mean ± s.d. where indicated. Comparisons between multiple groups were performed by analysis of variance (ANOVA) followed by Tukey post hoc testing. Comparisons between two samples were analyzed for homogeneity of variance using Levene's test and analyzed by student's t-test. Groups with Po0.05 were considered statistically significant.
